|
市場調查報告書
歐洲的藥品流通狀況
Pharmaceutical Distribution in Europe: Pfizer Breaks the Mold
|
本報告已在2011年12月21日停止出版。
2007年初Pfizer在英國採用了企業產品獨立直銷系統。這成為傳統醫藥流通系統的一大威脅，對批發業者、藥局、醫院等利害關係人造成巨大的影響。
專門於醫療產業相關廣泛調查的美國市調公司Decision Resources Inc. （總公司：美國Massachusetts洲），針對歐洲的藥品流通狀況進行調查分析，並系統整理調查結果後出版報告書"Pharmaceutical Distribution in Europe: Pfizer Breaks the Mold"。
本報告書內容包括：藥品的流通模式及Pfizer採用新流通系統的動機、對市場造成的影響、利害關係人的反應、未來發展前景等。內容綱要摘記如下：
- 實施概要
- 轉變中的藥品流通方式
- 採用直銷制度的動機
- Pfizer在德國和西班牙吃了閉門羹
- Pfizer在英國採用直銷方式銷售
- 其他製藥企業對流通制度的改變感興趣
- 英國藥品流通相關調查
- 批發業者的反應
- 藥局的反應
- 其他利害關係人的反應
- 政府的觀點
- 製藥產業及批發產業的未來發展前景及影響
Abstract
Introduction
Beginning March 2007, Pfi zer introduced a direct distribution system for its
products in the United Kingdom, making them available only from the company' s
sole appointed distributor rather than from a choice of wholesalers. This
approach, should it prove successful, threatens to overturn the established
model of pharmaceutical distribution, imposing enormous changes upon key
stakeholder groups-wholesalers, pharmacists, hospitals, dispensing doctors,
and government.
Get the Answers You Need to Shape Your Strategy
- Like Pfi zer, two-thirds of pharmaceutical companies have considered
changes to their European distribution systems, threatening what was in 2004 a
$130 billion pharmaceutical wholesale market for the region. What other pharma
companies are considering a switch to direct distribution, and why? How are
wholesalers adjusting their practices in anticipation of such a change in the
business environment?
- Pfi zer has reduced the discounts it provides to purchasers, changing from
a percentage of the purchase value to a fl at fee per pack; other companies
considering direct-to-pharmacy (DTP) distribution may follow suit. What
recourse do pharmacists and prescribers have in the face of this revenue loss?
What government involvement, if any, might help offset this loss? What impact
could this have on services provided?
- In 1991, GlaxoSmithKline (then-Glaxo) introduced a direct distribution
program in the United Kingdom, an excursion that may provide some insight into
potential outcomes of Pfi zer' s current venture. What changes has the company
made to this system in the intervening 16 years? How have wholesalers and
pharmacists responded to this program?
Scope
- The distribution market in fl ux: the changing patterns of pharmaceutical
distribution and companies' motives for adopting direct distribution.
- Pfi zer' s pursuit of DTP: the company' s attempts at direct distribution in
Germany, Spain, and the United Kingdom.
- Market impact: other multinational manufacturers interested in direct
distribution.
- Key stakeholders' response: reactions of wholesalers, pharmacists, and
dispensing doctors, as well as the government view of the program and the
ensuing investigation of U.K. pharma distribution.
- Outlook and implications: our forecast for the impact of DTP on future
drug distribution trends.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Changing Patterns of Pharmaceutical Distribution
- Motives for Adopting Direct Distribution
- Pfi zer Rebuffed in Germany and Spain
- Pfi zer Implements Direct Distribution in the United Kingdom
- Other Manufacturers Interested in Changing Their Distribution Systems
- Investigation of U.K. Pharmaceutical Distribution
- Wholesalers' Response
- Pharmacists' Response
- Other Stakeholders' Responses
- Government View
- Outlook and Implications for the Pharmaceutical and Wholesale Industries
Table:
- 1. Discounts Offered to Pfi zer' s Direct Distribution Pharmacy Customers
in the United Kingdom
Figure:
- 1. Timetable of Key Events in the Development of Direct-to-Pharmacy
Distribution in the United Kingdom
Sidebars:
- Glaxo' s Approach to Agency Distribution
- Single-Channel Distribution in Finland and Sweden
- Logistics Service Providers: New Competition for Traditional Wholesalers
|
